Special Issue "Recent Advances in Research into Vaccine Technologies"

A special issue of Vaccines (ISSN 2076-393X).

Deadline for manuscript submissions: closed (28 February 2022) | Viewed by 2132

Special Issue Editors

CF-UM-UP, Centre of Physics of University of Minho and Porto, Braga, Portugal
Interests: lipoplexes; liposomes; biophysics; bionanosystems; contact lenses; gene therapy; drug-delivery; vaccines
Centre of Molecular and Environmental Biology (CBMA), Department of Biology, University of Minho, 4710 Braga, Portugal
Interests: invasive fungal infections; fungal molecular identification; fungal pathogenesis; host-fungus interaction
Special Issues, Collections and Topics in MDPI journals
1. CF-UM-UP, Centro de Física das Universidades do Minho e Porto, Departamento de Física da Universidade do Minho, 4710-057 Braga, Portugal
2. CBMA, Centro de Biologia Molecular e Ambiental, Departamento de Biologia, Universidade do Minho, 4710-057 Braga, Portugal
Interests: nanocarriers; nanotherapeutics; membrane model systems; ADMET profiling; biophysical techniques
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Pathogenic infections are spreading rapidly in an increasingly globalized world due to migratory movements and cross-national contact. With globalization, certain restricted or geographically localized infections are also becoming global. Furthermore, the current pandemic has demonstrated the importance of an annual profilaxy against recurrent infections. This also creates a necessity to develop multipurpose vaccines, targeting different infectious agents. Concerns about weak immunogenicity, intrinsic in vivo instability and toxicity should be also a focus in vaccine development. These global challenges create an opportunity for the translation to the clinics of nanotechnology-based carriers for antigens and nucleic acids.

We welcome contributions including original research articles as well as field reviews relating to this research topic. The goal of the Special Issue is to provide an overview of the current state of the art, as well as to highlight recent discoveries and future prospects for nanotechnology-based vaccines.

Prof. Dr. Maria Elisabete C. D. Real Oliveira
Prof. Dr. Andreia Gomes
Dr. Paula Sampaio
Dr. Marlene Lucio
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • nanovaccines
  • nanobiotechnology
  • immunology
  • toxicology, antigen delivery
  • nucleic acid delivery
  • pandemic infections

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


Mutagenic Distinction between the Receptor-Binding and Fusion Subunits of the SARS-CoV-2 Spike Glycoprotein and Its Upshot
Vaccines 2021, 9(12), 1509; https://doi.org/10.3390/vaccines9121509 - 20 Dec 2021
Cited by 4 | Viewed by 1798
We observe that a residue R of the spike glycoprotein of SARS-CoV-2 that has mutated in one or more of the current variants of concern or interest, or under monitoring, rarely participates in a backbone hydrogen bond if R lies in the S [...] Read more.
We observe that a residue R of the spike glycoprotein of SARS-CoV-2 that has mutated in one or more of the current variants of concern or interest, or under monitoring, rarely participates in a backbone hydrogen bond if R lies in the S1 subunit and usually participates in one if R lies in the S2 subunit. A partial explanation for this based upon free energy is explored as a potentially general principle in the mutagenesis of viral glycoproteins. This observation could help target future vaccine cargos for the evolving coronavirus as well as more generally. A related study of the Delta and Omicron variants suggests that Delta was an energetically necessary intermediary in the evolution from Wuhan-Hu-1 to Omicron. Full article
(This article belongs to the Special Issue Recent Advances in Research into Vaccine Technologies)
Show Figures

Figure 1

Back to TopTop